Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, a...
Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma
About this item
Full title
Author / Creator
Short, K Detweiler , Rajkumar, S V , Larson, D , Buadi, F , Hayman, S , Dispenzieri, A , Gertz, M , Kumar, S , Mikhael, J , Roy, V , Kyle, R A and Lacy, M Q
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
We studied 174 consecutive patients with relapsed refractory multiple myeloma (MM) enrolled on a phase II clinical trial of pomalidomide plus low-dose dexamethasone at Mayo Clinic. Extramedullary disease (EMD) was present at the time of trial entry in 7.5% (13 of 174 patients). The rate of EMD in the first 3 years following diagnosis of MM was 3%....
Alternative Titles
Full title
Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3736849
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3736849
Other Identifiers
ISSN
0887-6924
E-ISSN
1476-5551
DOI
10.1038/leu.2011.29
